SlideShare a Scribd company logo
RADx Underserved Populations (RADx-UP)
Warren Kibbe
January 29th for IDIG
@wakibbe
OVERVIEW OF RADX PROGRAM
3
Project Description
RADx Tech Highly competitive, rapid three-phase challenge to identify the best candidates for
at-home or point-of-care tests for COVID-19.
RADx-Advanced Technology
Technology Platforms
(RADx-ATP)
Rapid scale-up of advanced POC technologies and laboratories to accelerate,
enhance and validate utility of ultra-high throughput machines and facilities.
RADx-Radical
(RADx-rad)
Develop and advance novel, non-traditional approaches or new applications of
existing approaches for testing.
RADx-Underserved
Populations (RADx-UP)
Interlinked community-engaged projects focused on implementation strategies to
enable and enhance testing of COVID-19 in underserved and/or vulnerable
populations.
Rapid Acceleration of
Diagnostics (RADx) Overview
4
Overarching Goal
Establish a robust pipeline of innovative diagnostic technologies to increase
national testing capacity.
Innovate Across the Testing Landscape
Expand the number, type, access, and throughput of testing technologies.
Optimize Technology Performance
Develop technology for a range of essential “Use Cases”
 At-home
 Point of Care (POC)
 Hospital
 Testing Laboratory
RADx Tech
5
Overarching Goal
Increase testing capacity and throughput by identifying existing and late-
stage testing platforms to achieve rapid scale-up or expanded
geographical placement.
 Emphasize differential POC testing to distinguish SARS-Cov-2 vs.
influenza.
 Establish rapid collaborations with key industry partners.
RADx-Advanced Technology Platforms
(RADx-ATP)
Support Scale-Up of High-Throughput Labs to
Add Capacity
Scale-up Late-Stage Technologies
6
Overarching Goal
Support new, non-traditional approaches and new applications of existing tools
that address gaps in COVID-19 testing and develop platforms that can be deployed
in future outbreaks of COVID-19 and other, yet unknown, diseases.
Example Research Technologies of Interest
 Wastewater-based detection of SARS-COV-2
 Single vesicle, exosome, and exRNA isolation for the detection of SARS-CoV-
2
 Chemosensory testing for COVID-19 screening
 Predicting viral-associated inflammatory disease severity in children with
laboratory diagnostics and artificial intelligence
 Multimodal COVID-19 surveillance methods for high-risk populations
RADx-Radical (RADx-rad)
7
Phase I: $300M Phase II: $200M
Build infrastructure Rapidly implement
testing, other capabilities
Integrate new
advances
Expand studies/
populations
September – November 2020 2021
RADx-Underserved Populations (RADx-UP)
Overarching Goals
 Enhance COVID-19 testing among underserved and vulnerable populations across the US.
 Develop/create a consortium of community-engaged research projects designed to rapidly implement
testing interventions.
 Strengthen the available data on disparities in infection rates, disease progression and outcomes, and
identify strategies to reduce these disparities in COVID-19 diagnostics.
INTRODUCTION OF RADX-UP
9
RADx-UP Strategies
• Expand capacity to test broadly for SARS-CoV-2 in highly affected
populations, including asymptomatic persons.
• Deploy validated point of care tests as available, including self-test
and saliva-based methods.
• Inform implementation of mitigation strategies based on isolation
and contact tracing to limit community transmission.
• Understand factors that contribute to COVID-19 disparities and
implement interventions to reduce these disparities.
• Establish infrastructure that could facilitate evaluation and distribution
of vaccines and therapeutics.
10
Overview
 Awarded 29 sites in FY20, 1 site in FY21
o Approximately 500,000 participants/tests
 Testing methods include a range of POC, pooled, & lab-based; PCR, antigen, and Ab:
o Abbott ID NOW, Roche cabas, Cepheid GeneXpert, Hologic Aptima/Panther Fusion, Advanta Dx, Quest Diagnostics LDT,
ThermoFisher, Infinity BiologiX, LabCorp, and custom tests
 Testing at prisons, mental health programs, in public housing & community centers
o Focus on rural and urban, Tribal, and aging communities
 Understand the factors associated with COVID-19 morbidity and mortality disparities and to lay
the foundation to reduce disparities for those underserved and vulnerable populations
 Closely partner with communities to develop and implement interventions to increase access
and uptake of testing
 Provide large-scale testing and collaborate across the consortium of projects to serve as a
resource for future studies and outreach
Program Information: $5M per site over 2 years; 30 sites
NOT-OD-20-121
Testing Research Projects: Large Networks, Consortia &
Research Centers
11
Overview
 Awarded 4 sites in FY20, 19 in FY21
 Testing methods include a range of POC, pooled, & lab-based; PCR, antigen, and Ab:
o Abbott ID NOW, Abbott Architect IgG Assay, Applied BioSystems, Cellex Rapid Test, KorvaLabs Curative SARS-Cov-2 Assay,
Cepheid GeneXpert, Cellex Rapid Test, Healgen, Quidel Sofia SARS antigen test, ThermoFisher, TaqPath, LabCorp, Inno
Diagnostics, and custom tests
 Testing at mobile-sites, community health centers, in public housing & at home
o Focus on individuals with medical comorbidities, substance use disorders or mental illness, and community
dwelling older adults
 Strengthen available data on disparities in infection rates and disease progression and
outcomes among underserved and vulnerable populations across the US
 Understand differences in testing access and uptake patterns
 Partner with communities to build the evidence-base of approaches to identify and address
disparities in diagnostic testing uptake and effectiveness
NOT-OD-20-120
Testing Research Projects: Community Collaborations &
Partnerships
Program Information: $2M per site over 2 years; 23 sites
12
Overview
 Awarded 5 projects in FY20, 11 in FY21
 Research conducted through community health centers, online surveys, public housing developments, and Tribal communities
o Focus on individuals with medical comorbidities, migrant and immigrant populations, Tribal populations, and rural and remote
communities
 Assess ethical, historical, healthcare, social, economic, and contextual factors surrounding
COVID-19 testing
 Investigate influence of cultural beliefs and attitudes, perceived expectations, and preferences
 Inform development of interventions and tools to increase access to and acceptability of testing
Social, Ethical and Behavioral Implications
Program Information: $1.2M per site over 2 years; 16 sites
NOT-OD-20-119
13
Overview
 Awarded to Duke/UNC
 Innovative ideas for data management, hub and spoke models of networked testing, and outreach to underserved communities
 Experience in developing new SARS-CoV-2 testing technologies
o Provide strong technical assistance to testing protocols and adoption/distribution of new, emerging technologies
 Serve as a national resource to coordinate across the RADx Consortium
 Provide overarching support and guidance in: (1) Administrative Operations and Logistics, (2)
COVID-19 Testing Technology, (3) Community and Health System Engagement and (4) Data
Collection, Integration and Sharing
 Support the pilot project programs: (1) Rapid pilot studies, (2) Community collaboration grants
RFA-OD-20-013
RADx-UP Coordinating Center (CDCC)
Program Information: $80M over 4 years
This Is RADx-UP:
Our Projects & The Communities We Serve
Projects Overview
Total Number Projects 69
Total Number of States and Territories 56 *includes Washington DC
Total Target Enrollment 683,220
Total Participants to be Tested 362,000
First Study Enrollment July 2020
Last Study Enrollment November 2022
States or Territories the Projects will Serve
17
NOT-OD-20-121, NOT-OD-20-120, NOT-OD-20-119 & RFA-OD-20-013
Together, funded sites and research projects propose to serve a diverse population set, with many projects serving
Hispanic/Latino and African American populations, as well as Asian Americans and American Indians/Alaska Natives.
RADx-UP Phase I Snapshot: 70 Funded Sites and Research Projects
3
5
15
19
24
25
33
41
Native Hawaiians and other Pacific Islanders
Underserved Rural Populations
Socioeconomically disadvantaged populations
Sexual and Gender Minorities
American Indians/Alaska Natives
Asian Americans
Blacks/African Americans
Hispanics/Latinos/as
Target Health Disparity Population Projects
Note: Some projects/sites address multiple target populations.
Number of Awards
18
NOT-OD-20-121, NOT-OD-20-120, NOT-OD-20-119 & RFA-OD-20-013
Together, funded sites and research projects propose to serve a diverse population set, with many projects serving
individuals with medical comorbidities known to increase risk of severe COVID-19, rural and remote communities, and
migrant and immigrant populations.
8
10
11
11
11
12
15
23
25
Residents of tribal lands or reservations
Public housing residents
Children and adolescents
Community dwelling older adults
Essential workers
Individuals with substance use disorders or serious mental illness
Migrant and immigrant populations
Rural and remote communities
Individuals with medical comorbidities known to increase risk of severe COVID-19
Target Vulnerable Population Projects (1/2)
RADx-UP Phase I Snapshot: 70 Funded Sites and Research Projects
Note: Some projects/sites address multiple target populations.
Number of Awards
19
NOT-OD-20-121, NOT-OD-20-120, NOT-OD-20-119 & RFA-OD-20-013
RADx-UP Phase I Snapshot: 70 Funded Sites and Research Projects
Funded sites and research projects also propose to serve the following additional vulnerable populations.
3
4
5
5
6
7
7
Residents of nursing homes and assisted living facilities
Individuals with disabilities, cognitive impairment or dementia, or communication disorders
Individuals living in congregate housing
Pregnant and post-partum women
Individuals involved with the criminal or juvenile justice systems
Communities exposed to high rates of air pollution or other toxic exposures
Homeless populations
Target Vulnerable Population Projects (2/2)
Note: Some projects/sites address multiple target populations.
Number of Awards
Number of Projects with Specific Target Population
46
42
31
21
18
17
17
16
5
2
2
1
Project Settings
Primary Languages of the Communities
Community Outreach Methods to be Used
community-based
COVID-19 Testing
25
Social, Ethical and Behavioral Implications (SEBI) Institutions
RADx-UP Phase I Awards
Note: There are two awards located in Los Angeles, CA and New York, NY each.
26
Social, Ethical and Behavioral Implications (SEBI) Participant Locations
RADx-UP Phase I Awards
Note: Cities listed are not exhaustive, as some projects only provided state-level information.
OVERVIEW OF RADX-UP CDCC
Coordination & Data Collection
Center
The RADx-UP CDCC is funded through NIH emergency cooperative agreement 1U24MD016258
Welcome from the RADx-UP CDCC Team
Duke Clinical Research
Institute (DCRI)
UNC Center for Health
Equity Research
Duke Department of
Biostatistics and Bioinformatics
30
 The RADx-UP Coordination and Data
Collection Center (CDCC) serves as a hub for all
RADx-UP funded projects
The RADx-UP CDCC
 Provides steadfast assistance to RADx-UP projects to optimize
engagement, outreach, testing strategies, data collection and
integration, and co-learning opportunities between and among
projects and to the communities that we serve
• Is led by the Duke Clinical Research Institute (DCRI),the Center
for Health Equity Research at UNC-Chapel Hill with support from
a key partner, Community-Campus Partnerships for Health
31
RADx-UP CDCC
Goals
Accelerate COVID-19 community implementation
science via an agile, flexible, participatory,
transparent and sustainable CDCC.
Support data collection, integration, and
sharing while preserving necessary data
protections.
Amplify and disseminate community best practices
for successful implementation of COVID-19 testing
strategies and vaccines.
Utilize RADx-UP infrastructure to
support COVID-19 research.
32
Communities are at the center of our
work.
Data sovereignty protections and
sharing with communities and
participants are essential in building
trust and being trustworthy.
Intentional support of study teams is
critical to streamline results and
troubleshoot.
Broad dissemination of program
activities, data, and best practices are
key.
Strategic partnerships will augment
community benefits from the program.
Impact will be broad and will inform
national guidance, strategy, and
response to COVID-19.
*To be collaboratively informed by NIH and the community
RADx-UP CDCC Guiding Principles – Draft*
33
RADx-UP CDCC
Principal Investigator Leadership: Michael Cohen‐Wolkowiez, MD, PhD, Giselle Corbie‐Smith, MD, MSc, Warren Kibbe, PhD, FACMI
Operations Director: Renee Pridgen
Program Director: Susan Knox
ADMINISTRATION AND COORDINATION CORE
Operational Lead: Donna Parker
ENGAGEMENT IMPACT TEAMS
COVID‐19 TESTING CORE
Core Leadership:
Chris Woods, MD, Thomas Denny, MSc, MPhil
Program Lead: Tim Veldman, PhD
Operational Lead: Barrie Harper
COMMUNITY ENGAGEMENT CORE
Core Leadership:
Al Richmond, Krista Perreira, PhD
Program Lead : Renee Leverty
Operational Lead: Crystal Cannon
DATA SCIENCE AND BIOSTATISTICAL CORE
Core Leadership:
Keith Marsolo, PhD, Lisa Wruck, PhD
Program Lead : Bhargav Adagarla
Operational Lead: Laura Johnson
RADx-UP
STEERING COMMITTEE &
EXTERNAL ADVISORY
BOARD
RADx-UP Awardees
SERVICES: Project Leadership, Communications, Evaluation
NIH Program Officers:
Dottie Castille, PhD
Beda Jean-Francois, PhD
NIH Project Scientist:
Fabienne Santel, MD, MPH
NIH Project Scientist:
Nadra Tyus, Dr.PH, MPH
NIH Project Scientist:
Partha Bhattacharyya, PhD
34
Administration &
Coordination
 Communication
 Committee oversight
 Processes, policies,
procedures
 Partnerships
 Evaluation
Community
Engagement
 Best practices
 Engagement Resource
Library
 COVID-19 Equity
Evidence Academy
 Community of Practice
 Community
Collaboration Grants
COVID-19 Testing
 Technical support
 Repository of emerging
technologies
 Testing selection &
implementation
 Research pilot studies
Data Science &
Statistics
 Data harmonization
 Security, privacy, and
protections
 Data exchange
 Data representation and
visualization
ENGAGEMENT IMPACT TEAMS
CDCC Cores
35
CDCC Engagement Impact Teams
• EIT Members: project management + community
engagement
• Single point of contact to awardees
• Support awardees
•Coordination, testing, community engagement, and data
collection and sharing
•Identify challenges and collaboratively generate solutions
•Testing and supplies, timeline management, community
access and engagement, recruitment and retention
challenges, and data use limitations, etc.
• Assist with troubleshooting
• Monitor progress
36
CDCC Awardee
Communication Objective:
Communication
Channels
Welcome via
Email
Data Exchange
Engagement
Impact Team
Outreach
Newsletters
Orientation
Session
Project-wide
Meetings
COVID-19 Equity
Evidence Academy
Provide regular communications
to RADx-UP awarded projects to:
• Support engagement, testing,
and data collection/integration
• Promote co-learning between
and among projects and the
communities that we serve
RADx-UP Draft Communication Plan
Program Activity Timeline
What’s
New
• The final Common Data Elements (CDEs) and Informed Consent Data Sharing (ICF)
Template Language are available on the RADx-UP Toolkit, http://radx-up.org/toolkit/
• Check in with your CDCC Engagement Impact Team to discuss questions or concerns
related to implementation on your project
• Steering Committee members have been invited and will meet Jan. 25
• RADx-UP website includes Resource Library
What’s
Next
• Details and RFAs for the Community Collaboration Mini-Grant Program and the Rapid
Research Pilot Project Grant Program will be announced
• COVID-19 Equity Evidence Academy “Translating Innovations in Testing” (Feb. 24-25)
• Team directory and collaboration space coming soon!
News, Deadlines & Reminders
It’s as Easy as 1, 2, 3 to Stay Connected…
1. Read the RADx-UP newsletter
2. Participate in RADx-UP Monthly Project-Wide Team
Meetings
3. Establish regular connections with your Engagement
Impact Team or contact us at RADx-UP-
CDCC@dm.duke.edu.
RADx-UP Website & Toolkit
• Visit Radx-up.org/ to find:
• Project Profiles
• News
• Grant Opportunities (forthcoming)
• Visit Radx-up.org/toolkit/ to find:
• Communication Materials
• A Data Toolkit
• Engagement Impact Team Directory
• Meeting Recordings
• And More!
RADx-UP Common Data Elements (CDEs):
Why Collect CDEs?
Givens: Community Impact
• The COVID-19 pandemic is having a dramatic impact on people’s lives, livelihoods,
and community interactions.
• It has highlighted health disparities. Many communities across the country are
facing more difficulties than others as they confront the pandemic.
• Underserved populations are concerned about research and how science and
government collects information from individuals, how that information is shared,
and how a participant’s identity could be exposed and exploited.
• Communities, including those serving Tribal Nations, have additional data rights
and responsibilities.
Givens: Notice of Special Interest (NOSI) Terms
• RADx-UP members are required to collect and share data, as outlined in NOSI terms:
• NIH is developing common data elements, which are standardized for multiple data sets across
different studies. Study data must be compatible to submit in required formats for person-
specific elements, such as demographics, social determinants of health and
characteristics; and COVID-19-specific elements.
• Recipients are expected to include the minimum NIH COVID-19 common data elements.
• Core common data elements are requested in a common format…
• NIH is requiring data sharing for all COVID-19 projects, where it is not prohibited (e.g., Tribal
data sovereignty).
• Recipients are expected to coordinate and share data with the CDCC and other projects
supported by the RADx-UP initiative and with considerations under tribal IRB processes.
• The NIH expects and supports the timely release and sharing of final research data from NIH-
supported studies for use by other researchers to expedite the translation of research
results into knowledge, products, and procedures to improve human health.
Purpose: Fight COVID-19 – Together
• RADx-UP is part of the $1.4 billion dollar NIH RADx initiative to help speed innovation in
the development and implementation of COVID-19 testing, vaccines, and related
technologies.
• One of the top priorities of the RADx initiative is creating the RADx Data Hub, a national
resource of RADx COVID-19 research data. Data collection and sharing is critical to the
success of the RADx initiative.
• NIH expects RADx-UP projects to participate as one consortium of interlinked community-
engaged research projects to understand, address, and solve COVID-19 health
disparities.
• Community centered research across all RADx projects will help to expedite the
translation of results into knowledge to improve the health of our communities.
• The RADx-UP CDCC is expected to provide the best guidance and support to RADx-UP
projects and the communities you serve, recognizing your experience, perspectives,
and project-specific requirements for data sharing.
Common Data Elements
Goals for the discussion
• Finalize CDEs for RADx-UP
• Sense of urgency, project
enrollment delays
• Agree on data sharing scenarios
• Align on next steps
IRB status as of
12/21/2020
Number of
projects
Not yet submitted 11
Some approvals received, more pending 8
Submitted, not approved 20
Approved, not yet enrolling 23
Enrolling, collecting begun 7
Tensions between RADx-UP goals
Lay foundation
to reduce
disparities
Understand
testing patterns
& factors
associated with
health
disparities
Need
to
build
trust
Need
to
collect
data
Collecting needed data while developing trust
1. NIH published the RADx-UP Data Harmonization Guidance
2. CDCC met with NIH, NLM, DR2 to discuss recommended RADx and RADx-UP
CDEs – initial Tier 1 version had 752 items
3. CDCC revised CDE and sent to NIH, NLM, DR2 for review
4. CDCC updated CDE based on feedback – version had 66 items
5. CDE survey sent to the Projects for their review and feedback
6. Met with Projects to review survey results and proposed CDE lists
7. Incorporated feedback and CDCC recommendations
Summary of Community/Participant Challenges
• CDE may impact participants’ comfort, willingness to getting tested
• Community trust will be impacted by collection of sensitive CDE (ex. identity)
• Participant burden due to length of CDE
• Wording of some CDE are not culturally sensitive
• Data sovereignty and sharing concerns associated with specific communities
Summary of Project Challenges
• Design of the project does not support CDE
• Survey is anonymous, so not obtaining consent
• Not enrolling individual participants / only have aggregate data
• High volume of visits per hour won’t allow for full CDE collection
• Staff burden
• Training needed for interviewers to administer the CDE as an oral interview
• Already IRB approved / started project / enrolling participants
• IRB or institution will not approve sharing some CDE with RADx-UP CDCC
• CDE do not align with the project’s specific goals or hypotheses
• Already asking similar questions/topics in project’s questionnaires
• Terminology in some CDE needs to be defined (ex. “stable housing”)
• CDE focus should be more on conditions and situations directly related to COVID-19
• Collecting extensive CDE to create a standard, long-standing, epidemiological dataset may impact the ability to
actually meet the project’s goals and the testing goals of RADx-UP
Common Data Elements:
We’ve heard you – let’s talk about your feedback
Will you be able to complete all of the RADx-UP
Common Data Elements questions with your study
participants?
13
52
13
52
0
10
20
30
40
50
60
Yes No
For which categories do you have recommendations
for alternative Common Data Elements?
4
1
8
10
5
10
4
7
11
4
7 7
0
2
4
6
8
10
12
Identity Consent Symptoms
(COVID-19)
Demographics Disability Employment Health
Insurance
Health Status Housing Medical
History
Medications Vaccine
Hesitancy
Specific Recommendations
Category/Question Source
Sexual orientation Projects’ community engaged work
Gender identity MTPC, PhenX
COVID-19 testing practices and beliefs Phen-X
Housing – house size (# rooms), density, age
groups of occupants
Kreuter & McQueen papers; projects
Ethnicity – expand categories for Pacific
Islander, Indigenous Mexicans
State of Hawaii; projects
Phone Number – change “work” to “other” Projects
Employment – add “part-time” and
“seasonal”
Projects
Health Insurance – include insurance type Projects
Next Steps
• Share template ICF language to enable data sharing w/RADx-UP
• Finalize the CDEs with NIH input
• Separate required and strongly recommended CDEs:
• Tier 1 (required)
• Tier 2 (strongly recommended, aligned with DR2 and PhenX toolkit CDEs)
• Distribute CDEs to RADx-UP projects for IRB submission and implementation
• Testing and Evaluation CDEs are forthcoming
Which category or categories contain questions you
anticipate not being able to collect?
31
10
7 8
25
9 8
19 18
22
42
8
0
5
10
15
20
25
30
35
40
45
Identity Consent Symptoms
(COVID-19)
Demographics Disability Employment Health
Insurance
Health Status Housing Medical
History
Medications Vaccine
Hesitancy
Specific Concerns
• Community/Participant Concerns:
• CDE may impact participants’ comfort, willingness to getting tested
• Community trust will be impacted by collection of sensitive CDE (ex. identity)
• Participant burden due to length of CDE
• Wording of some CDE are not culturally sensitive
• Data sovereignty and sharing concerns associated with specific communities
Specific Concerns
• Project Concerns:
• Design of the project does not support CDE
• Survey is anonymous, so not obtaining consent
• Not enrolling individual participants / only have aggregate data
• High volume of visits per hour won’t allow for full CDE collection
• Staff burden
• Training needed for interviewers to administer the CDE as an oral interview
• Already IRB approved / started project / enrolling participants
• IRB or institution will not approve sharing some CDE with RADx-UP CDCC
• CDE do not align with the project’s specific goals or hypotheses
• Already asking similar questions/topics in project’s questionnaires
• Terminology in some CDE needs to be defined (ex. “stable housing”)
Specific Concerns
• Relatedness to RADx-UP Goals
• CDE focus should be more on conditions and situations directly related to COVID-19
• Collecting extensive CDE to create a standard, long-standing, epidemiological dataset
may impact the ability to actually meet the project’s goals and the testing goals of
RADx-UP
QUESTIONS & ANSWERS

More Related Content

What's hot

Duke Industry Statistics Symposium - Real world evidence , EHRs and Cancer S...
Duke Industry Statistics Symposium -  Real world evidence , EHRs and Cancer S...Duke Industry Statistics Symposium -  Real world evidence , EHRs and Cancer S...
Duke Industry Statistics Symposium - Real world evidence , EHRs and Cancer S...
Warren Kibbe
 
Genomics and Computation in Precision Medicine March 2017
Genomics and Computation in Precision Medicine March 2017Genomics and Computation in Precision Medicine March 2017
Genomics and Computation in Precision Medicine March 2017
Warren Kibbe
 
Clinical Research Informatics Year-in-Review
Clinical Research Informatics Year-in-ReviewClinical Research Informatics Year-in-Review
Clinical Research Informatics Year-in-Review
Peter Embi
 
Hannes Smarason: Progress & Prospects in Genomics
Hannes Smarason: Progress & Prospects in GenomicsHannes Smarason: Progress & Prospects in Genomics
Hannes Smarason: Progress & Prospects in Genomics
Hannes Smárason
 
AACR 2018 Ask the Expert talk on NCI's Provocative Questions Initiatives
AACR 2018 Ask the Expert talk on NCI's Provocative Questions InitiativesAACR 2018 Ask the Expert talk on NCI's Provocative Questions Initiatives
AACR 2018 Ask the Expert talk on NCI's Provocative Questions Initiatives
Norbert Tavares, Ph.D.
 
Global Dementia Legacy Event: Dr Neil Buckholtz
Global Dementia Legacy Event: Dr Neil Buckholtz Global Dementia Legacy Event: Dr Neil Buckholtz
Global Dementia Legacy Event: Dr Neil Buckholtz
Department of Health
 
Secondary Data Analysis
Secondary Data AnalysisSecondary Data Analysis
Secondary Data Analysis
REY DECASTRO
 
Project Management_DM Presentation
Project Management_DM PresentationProject Management_DM Presentation
Project Management_DM PresentationDaniela Margiotta
 
PanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo Haupt
PanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo HauptPanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo Haupt
PanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo Haupt
KylieOBrien10
 
Population-Scale Research Efforts Enabled by Progress in Sequencing
Population-Scale Research Efforts Enabled by Progress in SequencingPopulation-Scale Research Efforts Enabled by Progress in Sequencing
Population-Scale Research Efforts Enabled by Progress in Sequencing
Hannes Smárason
 
Frontiers of Predictive Oncology and Computing
Frontiers of Predictive Oncology and ComputingFrontiers of Predictive Oncology and Computing
Frontiers of Predictive Oncology and Computing
Warren Kibbe
 
Strengthening data sharing for public health: ethical, legal and political is...
Strengthening data sharing for public health: ethical, legal and political is...Strengthening data sharing for public health: ethical, legal and political is...
Strengthening data sharing for public health: ethical, legal and political is...
ExternalEvents
 
The Role of Connected Diagnostics in Strengthening Regional, National and Con...
The Role of Connected Diagnostics in Strengthening Regional, National and Con...The Role of Connected Diagnostics in Strengthening Regional, National and Con...
The Role of Connected Diagnostics in Strengthening Regional, National and Con...
SystemOne
 
Engaging Patients in Research and Tool Development
Engaging Patients in Research and Tool DevelopmentEngaging Patients in Research and Tool Development
Engaging Patients in Research and Tool Development
Patient-Centered Outcomes Research Institute
 
Hannes Smarason: 2015 = An Inflection Point in Genomics
Hannes Smarason: 2015 = An Inflection Point in GenomicsHannes Smarason: 2015 = An Inflection Point in Genomics
Hannes Smarason: 2015 = An Inflection Point in Genomics
Hannes Smárason
 
jlme article final on NGS coverage n reimb issues w pat deverka
jlme article final on NGS coverage n reimb issues w pat deverkajlme article final on NGS coverage n reimb issues w pat deverka
jlme article final on NGS coverage n reimb issues w pat deverkaJennifer Dreyfus
 
Ensuring Values-based Assessments for Innovative Therapies: Brent Fraser (CADTH)
Ensuring Values-based Assessments for Innovative Therapies: Brent Fraser (CADTH)Ensuring Values-based Assessments for Innovative Therapies: Brent Fraser (CADTH)
Ensuring Values-based Assessments for Innovative Therapies: Brent Fraser (CADTH)
Canadian Organization for Rare Disorders
 
US Federal Cancer Moonshot- One Year Later
US Federal Cancer Moonshot- One Year LaterUS Federal Cancer Moonshot- One Year Later
US Federal Cancer Moonshot- One Year Later
Jerry Lee
 
MCDA for orphan_medicines_mg_dec2014
MCDA for orphan_medicines_mg_dec2014MCDA for orphan_medicines_mg_dec2014
MCDA for orphan_medicines_mg_dec2014
Office of Health Economics
 

What's hot (20)

Duke Industry Statistics Symposium - Real world evidence , EHRs and Cancer S...
Duke Industry Statistics Symposium -  Real world evidence , EHRs and Cancer S...Duke Industry Statistics Symposium -  Real world evidence , EHRs and Cancer S...
Duke Industry Statistics Symposium - Real world evidence , EHRs and Cancer S...
 
Genomics and Computation in Precision Medicine March 2017
Genomics and Computation in Precision Medicine March 2017Genomics and Computation in Precision Medicine March 2017
Genomics and Computation in Precision Medicine March 2017
 
Clinical Research Informatics Year-in-Review
Clinical Research Informatics Year-in-ReviewClinical Research Informatics Year-in-Review
Clinical Research Informatics Year-in-Review
 
Hannes Smarason: Progress & Prospects in Genomics
Hannes Smarason: Progress & Prospects in GenomicsHannes Smarason: Progress & Prospects in Genomics
Hannes Smarason: Progress & Prospects in Genomics
 
AACR 2018 Ask the Expert talk on NCI's Provocative Questions Initiatives
AACR 2018 Ask the Expert talk on NCI's Provocative Questions InitiativesAACR 2018 Ask the Expert talk on NCI's Provocative Questions Initiatives
AACR 2018 Ask the Expert talk on NCI's Provocative Questions Initiatives
 
Global Dementia Legacy Event: Dr Neil Buckholtz
Global Dementia Legacy Event: Dr Neil Buckholtz Global Dementia Legacy Event: Dr Neil Buckholtz
Global Dementia Legacy Event: Dr Neil Buckholtz
 
Secondary Data Analysis
Secondary Data AnalysisSecondary Data Analysis
Secondary Data Analysis
 
Project Management_DM Presentation
Project Management_DM PresentationProject Management_DM Presentation
Project Management_DM Presentation
 
Project Roadmap 2012-2016
Project Roadmap 2012-2016Project Roadmap 2012-2016
Project Roadmap 2012-2016
 
PanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo Haupt
PanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo HauptPanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo Haupt
PanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo Haupt
 
Population-Scale Research Efforts Enabled by Progress in Sequencing
Population-Scale Research Efforts Enabled by Progress in SequencingPopulation-Scale Research Efforts Enabled by Progress in Sequencing
Population-Scale Research Efforts Enabled by Progress in Sequencing
 
Frontiers of Predictive Oncology and Computing
Frontiers of Predictive Oncology and ComputingFrontiers of Predictive Oncology and Computing
Frontiers of Predictive Oncology and Computing
 
Strengthening data sharing for public health: ethical, legal and political is...
Strengthening data sharing for public health: ethical, legal and political is...Strengthening data sharing for public health: ethical, legal and political is...
Strengthening data sharing for public health: ethical, legal and political is...
 
The Role of Connected Diagnostics in Strengthening Regional, National and Con...
The Role of Connected Diagnostics in Strengthening Regional, National and Con...The Role of Connected Diagnostics in Strengthening Regional, National and Con...
The Role of Connected Diagnostics in Strengthening Regional, National and Con...
 
Engaging Patients in Research and Tool Development
Engaging Patients in Research and Tool DevelopmentEngaging Patients in Research and Tool Development
Engaging Patients in Research and Tool Development
 
Hannes Smarason: 2015 = An Inflection Point in Genomics
Hannes Smarason: 2015 = An Inflection Point in GenomicsHannes Smarason: 2015 = An Inflection Point in Genomics
Hannes Smarason: 2015 = An Inflection Point in Genomics
 
jlme article final on NGS coverage n reimb issues w pat deverka
jlme article final on NGS coverage n reimb issues w pat deverkajlme article final on NGS coverage n reimb issues w pat deverka
jlme article final on NGS coverage n reimb issues w pat deverka
 
Ensuring Values-based Assessments for Innovative Therapies: Brent Fraser (CADTH)
Ensuring Values-based Assessments for Innovative Therapies: Brent Fraser (CADTH)Ensuring Values-based Assessments for Innovative Therapies: Brent Fraser (CADTH)
Ensuring Values-based Assessments for Innovative Therapies: Brent Fraser (CADTH)
 
US Federal Cancer Moonshot- One Year Later
US Federal Cancer Moonshot- One Year LaterUS Federal Cancer Moonshot- One Year Later
US Federal Cancer Moonshot- One Year Later
 
MCDA for orphan_medicines_mg_dec2014
MCDA for orphan_medicines_mg_dec2014MCDA for orphan_medicines_mg_dec2014
MCDA for orphan_medicines_mg_dec2014
 

Similar to RADx-UP CDCC presentation for the NIH Disaster Interest Group

RADx-UP CDCC Overview November 2022
RADx-UP CDCC Overview November 2022RADx-UP CDCC Overview November 2022
RADx-UP CDCC Overview November 2022
Warren Kibbe
 
NIDA’s AIDS Research Program
NIDA’s AIDS Research ProgramNIDA’s AIDS Research Program
NIDA’s AIDS Research Program
HopkinsCFAR
 
Hertfordshire vaccine engagement tools may 2021
Hertfordshire vaccine engagement tools may 2021Hertfordshire vaccine engagement tools may 2021
Hertfordshire vaccine engagement tools may 2021
Professor Jim McManus AFBPsS,FFPH,CSci, FRSB, CPsychol
 
Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...
Rare Disease Patient Registries:  Key to Drug Development and Access Webinar ...Rare Disease Patient Registries:  Key to Drug Development and Access Webinar ...
Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...
Canadian Organization for Rare Disorders
 
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation ConferenceDay 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Canadian Organization for Rare Disorders
 
Global Globin 2020 Challenge: Developing capacity for gene variant data shari...
Global Globin 2020 Challenge: Developing capacity for gene variant data shari...Global Globin 2020 Challenge: Developing capacity for gene variant data shari...
Global Globin 2020 Challenge: Developing capacity for gene variant data shari...
Human Variome Project
 
Research to Guide Practice: Enhancing HIV/AIDs Platforms to Address NCDs in L...
Research to Guide Practice: Enhancing HIV/AIDs Platforms to Address NCDs in L...Research to Guide Practice: Enhancing HIV/AIDs Platforms to Address NCDs in L...
Research to Guide Practice: Enhancing HIV/AIDs Platforms to Address NCDs in L...
CORE Group
 
Key Populations and the HIV Epidemic: Lessons Learned in M&E and Future Direc...
Key Populations and the HIV Epidemic: Lessons Learned in M&E and Future Direc...Key Populations and the HIV Epidemic: Lessons Learned in M&E and Future Direc...
Key Populations and the HIV Epidemic: Lessons Learned in M&E and Future Direc...
MEASURE Evaluation
 
Vectors, environment and society unit
Vectors, environment and society unitVectors, environment and society unit
Vectors, environment and society unit
valéry ridde
 
DIAGNOSTICS - Application of nanodiagnostics in point-of-care tests for infec...
DIAGNOSTICS - Application of nanodiagnostics in point-of-care tests for infec...DIAGNOSTICS - Application of nanodiagnostics in point-of-care tests for infec...
DIAGNOSTICS - Application of nanodiagnostics in point-of-care tests for infec...
sudeepbhattacharyya
 
FROM KAMPALA TO CAPE TOWN
 FROM KAMPALA TO CAPE TOWN FROM KAMPALA TO CAPE TOWN
COUNTDOWN Russell Stothard - Launch 2015
COUNTDOWN Russell Stothard - Launch 2015COUNTDOWN Russell Stothard - Launch 2015
COUNTDOWN Russell Stothard - Launch 2015
COUNTDOWN on NTDs
 
Day 1: Cord Fall 2021 Conference Slides
Day 1: Cord Fall 2021 Conference SlidesDay 1: Cord Fall 2021 Conference Slides
Day 1: Cord Fall 2021 Conference Slides
Canadian Organization for Rare Disorders
 
Global Financing Facility (GFF) in Support of Every Woman Every Child Worksho...
Global Financing Facility (GFF) in Support of Every Woman Every Child Worksho...Global Financing Facility (GFF) in Support of Every Woman Every Child Worksho...
Global Financing Facility (GFF) in Support of Every Woman Every Child Worksho...
Global Financing Facility in support of Every Woman Every Child
 
Covid 19 surveillance-roadmap_final
Covid 19 surveillance-roadmap_finalCovid 19 surveillance-roadmap_final
Covid 19 surveillance-roadmap_final
Mumbaikar Le
 
1.Synopsis.The Multidimensional HIV/AIDS Model
1.Synopsis.The Multidimensional HIV/AIDS Model1.Synopsis.The Multidimensional HIV/AIDS Model
1.Synopsis.The Multidimensional HIV/AIDS Model
Mario Ricardo Calderón, MD, MPH, FPMER.
 
MNM COVID-19 Study
MNM COVID-19 StudyMNM COVID-19 Study
MNM COVID-19 Study
Michael Fritz
 

Similar to RADx-UP CDCC presentation for the NIH Disaster Interest Group (20)

RADx-UP CDCC Overview November 2022
RADx-UP CDCC Overview November 2022RADx-UP CDCC Overview November 2022
RADx-UP CDCC Overview November 2022
 
NIDA’s AIDS Research Program
NIDA’s AIDS Research ProgramNIDA’s AIDS Research Program
NIDA’s AIDS Research Program
 
Hertfordshire vaccine engagement tools may 2021
Hertfordshire vaccine engagement tools may 2021Hertfordshire vaccine engagement tools may 2021
Hertfordshire vaccine engagement tools may 2021
 
Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...
Rare Disease Patient Registries:  Key to Drug Development and Access Webinar ...Rare Disease Patient Registries:  Key to Drug Development and Access Webinar ...
Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...
 
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation ConferenceDay 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
Day 1: 9:15am-10:45am Panel Slides (Nov 18) Access to Innovation Conference
 
Global Globin 2020 Challenge: Developing capacity for gene variant data shari...
Global Globin 2020 Challenge: Developing capacity for gene variant data shari...Global Globin 2020 Challenge: Developing capacity for gene variant data shari...
Global Globin 2020 Challenge: Developing capacity for gene variant data shari...
 
4.Synopsis.Capacity.Building
4.Synopsis.Capacity.Building4.Synopsis.Capacity.Building
4.Synopsis.Capacity.Building
 
Research to Guide Practice: Enhancing HIV/AIDs Platforms to Address NCDs in L...
Research to Guide Practice: Enhancing HIV/AIDs Platforms to Address NCDs in L...Research to Guide Practice: Enhancing HIV/AIDs Platforms to Address NCDs in L...
Research to Guide Practice: Enhancing HIV/AIDs Platforms to Address NCDs in L...
 
Key Populations and the HIV Epidemic: Lessons Learned in M&E and Future Direc...
Key Populations and the HIV Epidemic: Lessons Learned in M&E and Future Direc...Key Populations and the HIV Epidemic: Lessons Learned in M&E and Future Direc...
Key Populations and the HIV Epidemic: Lessons Learned in M&E and Future Direc...
 
Vectors, environment and society unit
Vectors, environment and society unitVectors, environment and society unit
Vectors, environment and society unit
 
DIAGNOSTICS - Application of nanodiagnostics in point-of-care tests for infec...
DIAGNOSTICS - Application of nanodiagnostics in point-of-care tests for infec...DIAGNOSTICS - Application of nanodiagnostics in point-of-care tests for infec...
DIAGNOSTICS - Application of nanodiagnostics in point-of-care tests for infec...
 
FROM KAMPALA TO CAPE TOWN
 FROM KAMPALA TO CAPE TOWN FROM KAMPALA TO CAPE TOWN
FROM KAMPALA TO CAPE TOWN
 
COUNTDOWN Russell Stothard - Launch 2015
COUNTDOWN Russell Stothard - Launch 2015COUNTDOWN Russell Stothard - Launch 2015
COUNTDOWN Russell Stothard - Launch 2015
 
Day 1: Cord Fall 2021 Conference Slides
Day 1: Cord Fall 2021 Conference SlidesDay 1: Cord Fall 2021 Conference Slides
Day 1: Cord Fall 2021 Conference Slides
 
Global Financing Facility (GFF) in Support of Every Woman Every Child Worksho...
Global Financing Facility (GFF) in Support of Every Woman Every Child Worksho...Global Financing Facility (GFF) in Support of Every Woman Every Child Worksho...
Global Financing Facility (GFF) in Support of Every Woman Every Child Worksho...
 
Covid 19 surveillance-roadmap_final
Covid 19 surveillance-roadmap_finalCovid 19 surveillance-roadmap_final
Covid 19 surveillance-roadmap_final
 
1.Synopsis.Multidimensional_HIV:AIDS_Model
1.Synopsis.Multidimensional_HIV:AIDS_Model1.Synopsis.Multidimensional_HIV:AIDS_Model
1.Synopsis.Multidimensional_HIV:AIDS_Model
 
1.Synopsis.The Multidimensional HIV/AIDS Model
1.Synopsis.The Multidimensional HIV/AIDS Model1.Synopsis.The Multidimensional HIV/AIDS Model
1.Synopsis.The Multidimensional HIV/AIDS Model
 
MNM COVID-19 Study
MNM COVID-19 StudyMNM COVID-19 Study
MNM COVID-19 Study
 
Emphasis overview 5 10
Emphasis overview 5 10Emphasis overview 5 10
Emphasis overview 5 10
 

More from Warren Kibbe

CCDI Kibbe Wake Forest University Dec 2023.pptx
CCDI Kibbe Wake Forest University Dec 2023.pptxCCDI Kibbe Wake Forest University Dec 2023.pptx
CCDI Kibbe Wake Forest University Dec 2023.pptx
Warren Kibbe
 
Big Data Training for Cancer Research, Purdue, May 2023
Big Data Training for Cancer Research, Purdue, May 2023Big Data Training for Cancer Research, Purdue, May 2023
Big Data Training for Cancer Research, Purdue, May 2023
Warren Kibbe
 
CCDI Overview November 2022
CCDI Overview November 2022CCDI Overview November 2022
CCDI Overview November 2022
Warren Kibbe
 
CCDI Kibbe Big Data Training May 2022
CCDI Kibbe Big Data Training May 2022CCDI Kibbe Big Data Training May 2022
CCDI Kibbe Big Data Training May 2022
Warren Kibbe
 
NCATS CTSA N3C
NCATS CTSA N3C NCATS CTSA N3C
NCATS CTSA N3C
Warren Kibbe
 
NAACCR June 2020
NAACCR June 2020NAACCR June 2020
NAACCR June 2020
Warren Kibbe
 
ENAR 2020
ENAR 2020ENAR 2020
ENAR 2020
Warren Kibbe
 
ENAR 2020
ENAR 2020ENAR 2020
ENAR 2020
Warren Kibbe
 
Technology and connected health for population science kibbe duke jan 2020
Technology and connected health for population science kibbe duke jan 2020Technology and connected health for population science kibbe duke jan 2020
Technology and connected health for population science kibbe duke jan 2020
Warren Kibbe
 
Super computing 19 Cancer Computing Workshop Keynote
Super computing 19 Cancer Computing Workshop KeynoteSuper computing 19 Cancer Computing Workshop Keynote
Super computing 19 Cancer Computing Workshop Keynote
Warren Kibbe
 
Data Harmonization for a Molecularly Driven Health System
Data Harmonization for a Molecularly Driven Health SystemData Harmonization for a Molecularly Driven Health System
Data Harmonization for a Molecularly Driven Health System
Warren Kibbe
 
Data supporting precision oncology fda wakibbe
Data supporting precision oncology fda wakibbeData supporting precision oncology fda wakibbe
Data supporting precision oncology fda wakibbe
Warren Kibbe
 
Role of data in precision oncology
Role of data in precision oncologyRole of data in precision oncology
Role of data in precision oncology
Warren Kibbe
 
Data Harmonization for a Molecularly Driven Health System
Data Harmonization for a Molecularly Driven Health SystemData Harmonization for a Molecularly Driven Health System
Data Harmonization for a Molecularly Driven Health System
Warren Kibbe
 
Data sharing Webinar March 2019
Data sharing Webinar March  2019Data sharing Webinar March  2019
Data sharing Webinar March 2019
Warren Kibbe
 
Data in precision oncology SAMSI Precision Medicine Meeting mar 2019
Data in precision oncology SAMSI Precision Medicine Meeting mar 2019Data in precision oncology SAMSI Precision Medicine Meeting mar 2019
Data in precision oncology SAMSI Precision Medicine Meeting mar 2019
Warren Kibbe
 
Opportunities for computing in cancer research
Opportunities for computing in cancer researchOpportunities for computing in cancer research
Opportunities for computing in cancer research
Warren Kibbe
 
Opportunities in technology and connected health for population science
Opportunities in technology and connected health for population science Opportunities in technology and connected health for population science
Opportunities in technology and connected health for population science
Warren Kibbe
 
HPC, Machine Learning, and Big Data
HPC, Machine Learning, and Big DataHPC, Machine Learning, and Big Data
HPC, Machine Learning, and Big Data
Warren Kibbe
 
Ci4CC year in review - October 2018
Ci4CC year in review  - October 2018Ci4CC year in review  - October 2018
Ci4CC year in review - October 2018
Warren Kibbe
 

More from Warren Kibbe (20)

CCDI Kibbe Wake Forest University Dec 2023.pptx
CCDI Kibbe Wake Forest University Dec 2023.pptxCCDI Kibbe Wake Forest University Dec 2023.pptx
CCDI Kibbe Wake Forest University Dec 2023.pptx
 
Big Data Training for Cancer Research, Purdue, May 2023
Big Data Training for Cancer Research, Purdue, May 2023Big Data Training for Cancer Research, Purdue, May 2023
Big Data Training for Cancer Research, Purdue, May 2023
 
CCDI Overview November 2022
CCDI Overview November 2022CCDI Overview November 2022
CCDI Overview November 2022
 
CCDI Kibbe Big Data Training May 2022
CCDI Kibbe Big Data Training May 2022CCDI Kibbe Big Data Training May 2022
CCDI Kibbe Big Data Training May 2022
 
NCATS CTSA N3C
NCATS CTSA N3C NCATS CTSA N3C
NCATS CTSA N3C
 
NAACCR June 2020
NAACCR June 2020NAACCR June 2020
NAACCR June 2020
 
ENAR 2020
ENAR 2020ENAR 2020
ENAR 2020
 
ENAR 2020
ENAR 2020ENAR 2020
ENAR 2020
 
Technology and connected health for population science kibbe duke jan 2020
Technology and connected health for population science kibbe duke jan 2020Technology and connected health for population science kibbe duke jan 2020
Technology and connected health for population science kibbe duke jan 2020
 
Super computing 19 Cancer Computing Workshop Keynote
Super computing 19 Cancer Computing Workshop KeynoteSuper computing 19 Cancer Computing Workshop Keynote
Super computing 19 Cancer Computing Workshop Keynote
 
Data Harmonization for a Molecularly Driven Health System
Data Harmonization for a Molecularly Driven Health SystemData Harmonization for a Molecularly Driven Health System
Data Harmonization for a Molecularly Driven Health System
 
Data supporting precision oncology fda wakibbe
Data supporting precision oncology fda wakibbeData supporting precision oncology fda wakibbe
Data supporting precision oncology fda wakibbe
 
Role of data in precision oncology
Role of data in precision oncologyRole of data in precision oncology
Role of data in precision oncology
 
Data Harmonization for a Molecularly Driven Health System
Data Harmonization for a Molecularly Driven Health SystemData Harmonization for a Molecularly Driven Health System
Data Harmonization for a Molecularly Driven Health System
 
Data sharing Webinar March 2019
Data sharing Webinar March  2019Data sharing Webinar March  2019
Data sharing Webinar March 2019
 
Data in precision oncology SAMSI Precision Medicine Meeting mar 2019
Data in precision oncology SAMSI Precision Medicine Meeting mar 2019Data in precision oncology SAMSI Precision Medicine Meeting mar 2019
Data in precision oncology SAMSI Precision Medicine Meeting mar 2019
 
Opportunities for computing in cancer research
Opportunities for computing in cancer researchOpportunities for computing in cancer research
Opportunities for computing in cancer research
 
Opportunities in technology and connected health for population science
Opportunities in technology and connected health for population science Opportunities in technology and connected health for population science
Opportunities in technology and connected health for population science
 
HPC, Machine Learning, and Big Data
HPC, Machine Learning, and Big DataHPC, Machine Learning, and Big Data
HPC, Machine Learning, and Big Data
 
Ci4CC year in review - October 2018
Ci4CC year in review  - October 2018Ci4CC year in review  - October 2018
Ci4CC year in review - October 2018
 

Recently uploaded

Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
Pictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdfPictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdf
Dr. Rabia Inam Gandapore
 
Top-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptxTop-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptx
SwisschemDerma
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
SwastikAyurveda
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
ShashankRoodkee
 
Vision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of opticsVision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of optics
Sai Sailesh Kumar Goothy
 

Recently uploaded (20)

Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
Pictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdfPictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdf
 
Top-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptxTop-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptx
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
 
Vision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of opticsVision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of optics
 

RADx-UP CDCC presentation for the NIH Disaster Interest Group

  • 1. RADx Underserved Populations (RADx-UP) Warren Kibbe January 29th for IDIG @wakibbe
  • 3. 3 Project Description RADx Tech Highly competitive, rapid three-phase challenge to identify the best candidates for at-home or point-of-care tests for COVID-19. RADx-Advanced Technology Technology Platforms (RADx-ATP) Rapid scale-up of advanced POC technologies and laboratories to accelerate, enhance and validate utility of ultra-high throughput machines and facilities. RADx-Radical (RADx-rad) Develop and advance novel, non-traditional approaches or new applications of existing approaches for testing. RADx-Underserved Populations (RADx-UP) Interlinked community-engaged projects focused on implementation strategies to enable and enhance testing of COVID-19 in underserved and/or vulnerable populations. Rapid Acceleration of Diagnostics (RADx) Overview
  • 4. 4 Overarching Goal Establish a robust pipeline of innovative diagnostic technologies to increase national testing capacity. Innovate Across the Testing Landscape Expand the number, type, access, and throughput of testing technologies. Optimize Technology Performance Develop technology for a range of essential “Use Cases”  At-home  Point of Care (POC)  Hospital  Testing Laboratory RADx Tech
  • 5. 5 Overarching Goal Increase testing capacity and throughput by identifying existing and late- stage testing platforms to achieve rapid scale-up or expanded geographical placement.  Emphasize differential POC testing to distinguish SARS-Cov-2 vs. influenza.  Establish rapid collaborations with key industry partners. RADx-Advanced Technology Platforms (RADx-ATP) Support Scale-Up of High-Throughput Labs to Add Capacity Scale-up Late-Stage Technologies
  • 6. 6 Overarching Goal Support new, non-traditional approaches and new applications of existing tools that address gaps in COVID-19 testing and develop platforms that can be deployed in future outbreaks of COVID-19 and other, yet unknown, diseases. Example Research Technologies of Interest  Wastewater-based detection of SARS-COV-2  Single vesicle, exosome, and exRNA isolation for the detection of SARS-CoV- 2  Chemosensory testing for COVID-19 screening  Predicting viral-associated inflammatory disease severity in children with laboratory diagnostics and artificial intelligence  Multimodal COVID-19 surveillance methods for high-risk populations RADx-Radical (RADx-rad)
  • 7. 7 Phase I: $300M Phase II: $200M Build infrastructure Rapidly implement testing, other capabilities Integrate new advances Expand studies/ populations September – November 2020 2021 RADx-Underserved Populations (RADx-UP) Overarching Goals  Enhance COVID-19 testing among underserved and vulnerable populations across the US.  Develop/create a consortium of community-engaged research projects designed to rapidly implement testing interventions.  Strengthen the available data on disparities in infection rates, disease progression and outcomes, and identify strategies to reduce these disparities in COVID-19 diagnostics.
  • 9. 9 RADx-UP Strategies • Expand capacity to test broadly for SARS-CoV-2 in highly affected populations, including asymptomatic persons. • Deploy validated point of care tests as available, including self-test and saliva-based methods. • Inform implementation of mitigation strategies based on isolation and contact tracing to limit community transmission. • Understand factors that contribute to COVID-19 disparities and implement interventions to reduce these disparities. • Establish infrastructure that could facilitate evaluation and distribution of vaccines and therapeutics.
  • 10. 10 Overview  Awarded 29 sites in FY20, 1 site in FY21 o Approximately 500,000 participants/tests  Testing methods include a range of POC, pooled, & lab-based; PCR, antigen, and Ab: o Abbott ID NOW, Roche cabas, Cepheid GeneXpert, Hologic Aptima/Panther Fusion, Advanta Dx, Quest Diagnostics LDT, ThermoFisher, Infinity BiologiX, LabCorp, and custom tests  Testing at prisons, mental health programs, in public housing & community centers o Focus on rural and urban, Tribal, and aging communities  Understand the factors associated with COVID-19 morbidity and mortality disparities and to lay the foundation to reduce disparities for those underserved and vulnerable populations  Closely partner with communities to develop and implement interventions to increase access and uptake of testing  Provide large-scale testing and collaborate across the consortium of projects to serve as a resource for future studies and outreach Program Information: $5M per site over 2 years; 30 sites NOT-OD-20-121 Testing Research Projects: Large Networks, Consortia & Research Centers
  • 11. 11 Overview  Awarded 4 sites in FY20, 19 in FY21  Testing methods include a range of POC, pooled, & lab-based; PCR, antigen, and Ab: o Abbott ID NOW, Abbott Architect IgG Assay, Applied BioSystems, Cellex Rapid Test, KorvaLabs Curative SARS-Cov-2 Assay, Cepheid GeneXpert, Cellex Rapid Test, Healgen, Quidel Sofia SARS antigen test, ThermoFisher, TaqPath, LabCorp, Inno Diagnostics, and custom tests  Testing at mobile-sites, community health centers, in public housing & at home o Focus on individuals with medical comorbidities, substance use disorders or mental illness, and community dwelling older adults  Strengthen available data on disparities in infection rates and disease progression and outcomes among underserved and vulnerable populations across the US  Understand differences in testing access and uptake patterns  Partner with communities to build the evidence-base of approaches to identify and address disparities in diagnostic testing uptake and effectiveness NOT-OD-20-120 Testing Research Projects: Community Collaborations & Partnerships Program Information: $2M per site over 2 years; 23 sites
  • 12. 12 Overview  Awarded 5 projects in FY20, 11 in FY21  Research conducted through community health centers, online surveys, public housing developments, and Tribal communities o Focus on individuals with medical comorbidities, migrant and immigrant populations, Tribal populations, and rural and remote communities  Assess ethical, historical, healthcare, social, economic, and contextual factors surrounding COVID-19 testing  Investigate influence of cultural beliefs and attitudes, perceived expectations, and preferences  Inform development of interventions and tools to increase access to and acceptability of testing Social, Ethical and Behavioral Implications Program Information: $1.2M per site over 2 years; 16 sites NOT-OD-20-119
  • 13. 13 Overview  Awarded to Duke/UNC  Innovative ideas for data management, hub and spoke models of networked testing, and outreach to underserved communities  Experience in developing new SARS-CoV-2 testing technologies o Provide strong technical assistance to testing protocols and adoption/distribution of new, emerging technologies  Serve as a national resource to coordinate across the RADx Consortium  Provide overarching support and guidance in: (1) Administrative Operations and Logistics, (2) COVID-19 Testing Technology, (3) Community and Health System Engagement and (4) Data Collection, Integration and Sharing  Support the pilot project programs: (1) Rapid pilot studies, (2) Community collaboration grants RFA-OD-20-013 RADx-UP Coordinating Center (CDCC) Program Information: $80M over 4 years
  • 14. This Is RADx-UP: Our Projects & The Communities We Serve
  • 15. Projects Overview Total Number Projects 69 Total Number of States and Territories 56 *includes Washington DC Total Target Enrollment 683,220 Total Participants to be Tested 362,000 First Study Enrollment July 2020 Last Study Enrollment November 2022
  • 16. States or Territories the Projects will Serve
  • 17. 17 NOT-OD-20-121, NOT-OD-20-120, NOT-OD-20-119 & RFA-OD-20-013 Together, funded sites and research projects propose to serve a diverse population set, with many projects serving Hispanic/Latino and African American populations, as well as Asian Americans and American Indians/Alaska Natives. RADx-UP Phase I Snapshot: 70 Funded Sites and Research Projects 3 5 15 19 24 25 33 41 Native Hawaiians and other Pacific Islanders Underserved Rural Populations Socioeconomically disadvantaged populations Sexual and Gender Minorities American Indians/Alaska Natives Asian Americans Blacks/African Americans Hispanics/Latinos/as Target Health Disparity Population Projects Note: Some projects/sites address multiple target populations. Number of Awards
  • 18. 18 NOT-OD-20-121, NOT-OD-20-120, NOT-OD-20-119 & RFA-OD-20-013 Together, funded sites and research projects propose to serve a diverse population set, with many projects serving individuals with medical comorbidities known to increase risk of severe COVID-19, rural and remote communities, and migrant and immigrant populations. 8 10 11 11 11 12 15 23 25 Residents of tribal lands or reservations Public housing residents Children and adolescents Community dwelling older adults Essential workers Individuals with substance use disorders or serious mental illness Migrant and immigrant populations Rural and remote communities Individuals with medical comorbidities known to increase risk of severe COVID-19 Target Vulnerable Population Projects (1/2) RADx-UP Phase I Snapshot: 70 Funded Sites and Research Projects Note: Some projects/sites address multiple target populations. Number of Awards
  • 19. 19 NOT-OD-20-121, NOT-OD-20-120, NOT-OD-20-119 & RFA-OD-20-013 RADx-UP Phase I Snapshot: 70 Funded Sites and Research Projects Funded sites and research projects also propose to serve the following additional vulnerable populations. 3 4 5 5 6 7 7 Residents of nursing homes and assisted living facilities Individuals with disabilities, cognitive impairment or dementia, or communication disorders Individuals living in congregate housing Pregnant and post-partum women Individuals involved with the criminal or juvenile justice systems Communities exposed to high rates of air pollution or other toxic exposures Homeless populations Target Vulnerable Population Projects (2/2) Note: Some projects/sites address multiple target populations. Number of Awards
  • 20. Number of Projects with Specific Target Population 46 42 31 21 18 17 17 16 5 2 2 1
  • 22. Primary Languages of the Communities
  • 23. Community Outreach Methods to be Used community-based
  • 25. 25 Social, Ethical and Behavioral Implications (SEBI) Institutions RADx-UP Phase I Awards Note: There are two awards located in Los Angeles, CA and New York, NY each.
  • 26. 26 Social, Ethical and Behavioral Implications (SEBI) Participant Locations RADx-UP Phase I Awards Note: Cities listed are not exhaustive, as some projects only provided state-level information.
  • 28. Coordination & Data Collection Center The RADx-UP CDCC is funded through NIH emergency cooperative agreement 1U24MD016258
  • 29. Welcome from the RADx-UP CDCC Team Duke Clinical Research Institute (DCRI) UNC Center for Health Equity Research Duke Department of Biostatistics and Bioinformatics
  • 30. 30  The RADx-UP Coordination and Data Collection Center (CDCC) serves as a hub for all RADx-UP funded projects The RADx-UP CDCC  Provides steadfast assistance to RADx-UP projects to optimize engagement, outreach, testing strategies, data collection and integration, and co-learning opportunities between and among projects and to the communities that we serve • Is led by the Duke Clinical Research Institute (DCRI),the Center for Health Equity Research at UNC-Chapel Hill with support from a key partner, Community-Campus Partnerships for Health
  • 31. 31 RADx-UP CDCC Goals Accelerate COVID-19 community implementation science via an agile, flexible, participatory, transparent and sustainable CDCC. Support data collection, integration, and sharing while preserving necessary data protections. Amplify and disseminate community best practices for successful implementation of COVID-19 testing strategies and vaccines. Utilize RADx-UP infrastructure to support COVID-19 research.
  • 32. 32 Communities are at the center of our work. Data sovereignty protections and sharing with communities and participants are essential in building trust and being trustworthy. Intentional support of study teams is critical to streamline results and troubleshoot. Broad dissemination of program activities, data, and best practices are key. Strategic partnerships will augment community benefits from the program. Impact will be broad and will inform national guidance, strategy, and response to COVID-19. *To be collaboratively informed by NIH and the community RADx-UP CDCC Guiding Principles – Draft*
  • 33. 33 RADx-UP CDCC Principal Investigator Leadership: Michael Cohen‐Wolkowiez, MD, PhD, Giselle Corbie‐Smith, MD, MSc, Warren Kibbe, PhD, FACMI Operations Director: Renee Pridgen Program Director: Susan Knox ADMINISTRATION AND COORDINATION CORE Operational Lead: Donna Parker ENGAGEMENT IMPACT TEAMS COVID‐19 TESTING CORE Core Leadership: Chris Woods, MD, Thomas Denny, MSc, MPhil Program Lead: Tim Veldman, PhD Operational Lead: Barrie Harper COMMUNITY ENGAGEMENT CORE Core Leadership: Al Richmond, Krista Perreira, PhD Program Lead : Renee Leverty Operational Lead: Crystal Cannon DATA SCIENCE AND BIOSTATISTICAL CORE Core Leadership: Keith Marsolo, PhD, Lisa Wruck, PhD Program Lead : Bhargav Adagarla Operational Lead: Laura Johnson RADx-UP STEERING COMMITTEE & EXTERNAL ADVISORY BOARD RADx-UP Awardees SERVICES: Project Leadership, Communications, Evaluation NIH Program Officers: Dottie Castille, PhD Beda Jean-Francois, PhD NIH Project Scientist: Fabienne Santel, MD, MPH NIH Project Scientist: Nadra Tyus, Dr.PH, MPH NIH Project Scientist: Partha Bhattacharyya, PhD
  • 34. 34 Administration & Coordination  Communication  Committee oversight  Processes, policies, procedures  Partnerships  Evaluation Community Engagement  Best practices  Engagement Resource Library  COVID-19 Equity Evidence Academy  Community of Practice  Community Collaboration Grants COVID-19 Testing  Technical support  Repository of emerging technologies  Testing selection & implementation  Research pilot studies Data Science & Statistics  Data harmonization  Security, privacy, and protections  Data exchange  Data representation and visualization ENGAGEMENT IMPACT TEAMS CDCC Cores
  • 35. 35 CDCC Engagement Impact Teams • EIT Members: project management + community engagement • Single point of contact to awardees • Support awardees •Coordination, testing, community engagement, and data collection and sharing •Identify challenges and collaboratively generate solutions •Testing and supplies, timeline management, community access and engagement, recruitment and retention challenges, and data use limitations, etc. • Assist with troubleshooting • Monitor progress
  • 36. 36 CDCC Awardee Communication Objective: Communication Channels Welcome via Email Data Exchange Engagement Impact Team Outreach Newsletters Orientation Session Project-wide Meetings COVID-19 Equity Evidence Academy Provide regular communications to RADx-UP awarded projects to: • Support engagement, testing, and data collection/integration • Promote co-learning between and among projects and the communities that we serve RADx-UP Draft Communication Plan
  • 37. Program Activity Timeline What’s New • The final Common Data Elements (CDEs) and Informed Consent Data Sharing (ICF) Template Language are available on the RADx-UP Toolkit, http://radx-up.org/toolkit/ • Check in with your CDCC Engagement Impact Team to discuss questions or concerns related to implementation on your project • Steering Committee members have been invited and will meet Jan. 25 • RADx-UP website includes Resource Library What’s Next • Details and RFAs for the Community Collaboration Mini-Grant Program and the Rapid Research Pilot Project Grant Program will be announced • COVID-19 Equity Evidence Academy “Translating Innovations in Testing” (Feb. 24-25) • Team directory and collaboration space coming soon!
  • 38. News, Deadlines & Reminders It’s as Easy as 1, 2, 3 to Stay Connected… 1. Read the RADx-UP newsletter 2. Participate in RADx-UP Monthly Project-Wide Team Meetings 3. Establish regular connections with your Engagement Impact Team or contact us at RADx-UP- CDCC@dm.duke.edu.
  • 39. RADx-UP Website & Toolkit • Visit Radx-up.org/ to find: • Project Profiles • News • Grant Opportunities (forthcoming) • Visit Radx-up.org/toolkit/ to find: • Communication Materials • A Data Toolkit • Engagement Impact Team Directory • Meeting Recordings • And More!
  • 40. RADx-UP Common Data Elements (CDEs): Why Collect CDEs?
  • 41.
  • 42. Givens: Community Impact • The COVID-19 pandemic is having a dramatic impact on people’s lives, livelihoods, and community interactions. • It has highlighted health disparities. Many communities across the country are facing more difficulties than others as they confront the pandemic. • Underserved populations are concerned about research and how science and government collects information from individuals, how that information is shared, and how a participant’s identity could be exposed and exploited. • Communities, including those serving Tribal Nations, have additional data rights and responsibilities.
  • 43. Givens: Notice of Special Interest (NOSI) Terms • RADx-UP members are required to collect and share data, as outlined in NOSI terms: • NIH is developing common data elements, which are standardized for multiple data sets across different studies. Study data must be compatible to submit in required formats for person- specific elements, such as demographics, social determinants of health and characteristics; and COVID-19-specific elements. • Recipients are expected to include the minimum NIH COVID-19 common data elements. • Core common data elements are requested in a common format… • NIH is requiring data sharing for all COVID-19 projects, where it is not prohibited (e.g., Tribal data sovereignty). • Recipients are expected to coordinate and share data with the CDCC and other projects supported by the RADx-UP initiative and with considerations under tribal IRB processes. • The NIH expects and supports the timely release and sharing of final research data from NIH- supported studies for use by other researchers to expedite the translation of research results into knowledge, products, and procedures to improve human health.
  • 44. Purpose: Fight COVID-19 – Together • RADx-UP is part of the $1.4 billion dollar NIH RADx initiative to help speed innovation in the development and implementation of COVID-19 testing, vaccines, and related technologies. • One of the top priorities of the RADx initiative is creating the RADx Data Hub, a national resource of RADx COVID-19 research data. Data collection and sharing is critical to the success of the RADx initiative. • NIH expects RADx-UP projects to participate as one consortium of interlinked community- engaged research projects to understand, address, and solve COVID-19 health disparities. • Community centered research across all RADx projects will help to expedite the translation of results into knowledge to improve the health of our communities. • The RADx-UP CDCC is expected to provide the best guidance and support to RADx-UP projects and the communities you serve, recognizing your experience, perspectives, and project-specific requirements for data sharing.
  • 46. Goals for the discussion • Finalize CDEs for RADx-UP • Sense of urgency, project enrollment delays • Agree on data sharing scenarios • Align on next steps IRB status as of 12/21/2020 Number of projects Not yet submitted 11 Some approvals received, more pending 8 Submitted, not approved 20 Approved, not yet enrolling 23 Enrolling, collecting begun 7
  • 47. Tensions between RADx-UP goals Lay foundation to reduce disparities Understand testing patterns & factors associated with health disparities Need to build trust Need to collect data
  • 48. Collecting needed data while developing trust 1. NIH published the RADx-UP Data Harmonization Guidance 2. CDCC met with NIH, NLM, DR2 to discuss recommended RADx and RADx-UP CDEs – initial Tier 1 version had 752 items 3. CDCC revised CDE and sent to NIH, NLM, DR2 for review 4. CDCC updated CDE based on feedback – version had 66 items 5. CDE survey sent to the Projects for their review and feedback 6. Met with Projects to review survey results and proposed CDE lists 7. Incorporated feedback and CDCC recommendations
  • 49. Summary of Community/Participant Challenges • CDE may impact participants’ comfort, willingness to getting tested • Community trust will be impacted by collection of sensitive CDE (ex. identity) • Participant burden due to length of CDE • Wording of some CDE are not culturally sensitive • Data sovereignty and sharing concerns associated with specific communities
  • 50. Summary of Project Challenges • Design of the project does not support CDE • Survey is anonymous, so not obtaining consent • Not enrolling individual participants / only have aggregate data • High volume of visits per hour won’t allow for full CDE collection • Staff burden • Training needed for interviewers to administer the CDE as an oral interview • Already IRB approved / started project / enrolling participants • IRB or institution will not approve sharing some CDE with RADx-UP CDCC • CDE do not align with the project’s specific goals or hypotheses • Already asking similar questions/topics in project’s questionnaires • Terminology in some CDE needs to be defined (ex. “stable housing”) • CDE focus should be more on conditions and situations directly related to COVID-19 • Collecting extensive CDE to create a standard, long-standing, epidemiological dataset may impact the ability to actually meet the project’s goals and the testing goals of RADx-UP
  • 51. Common Data Elements: We’ve heard you – let’s talk about your feedback
  • 52. Will you be able to complete all of the RADx-UP Common Data Elements questions with your study participants?
  • 54. For which categories do you have recommendations for alternative Common Data Elements?
  • 55. 4 1 8 10 5 10 4 7 11 4 7 7 0 2 4 6 8 10 12 Identity Consent Symptoms (COVID-19) Demographics Disability Employment Health Insurance Health Status Housing Medical History Medications Vaccine Hesitancy
  • 56. Specific Recommendations Category/Question Source Sexual orientation Projects’ community engaged work Gender identity MTPC, PhenX COVID-19 testing practices and beliefs Phen-X Housing – house size (# rooms), density, age groups of occupants Kreuter & McQueen papers; projects Ethnicity – expand categories for Pacific Islander, Indigenous Mexicans State of Hawaii; projects Phone Number – change “work” to “other” Projects Employment – add “part-time” and “seasonal” Projects Health Insurance – include insurance type Projects
  • 57. Next Steps • Share template ICF language to enable data sharing w/RADx-UP • Finalize the CDEs with NIH input • Separate required and strongly recommended CDEs: • Tier 1 (required) • Tier 2 (strongly recommended, aligned with DR2 and PhenX toolkit CDEs) • Distribute CDEs to RADx-UP projects for IRB submission and implementation • Testing and Evaluation CDEs are forthcoming
  • 58. Which category or categories contain questions you anticipate not being able to collect?
  • 59. 31 10 7 8 25 9 8 19 18 22 42 8 0 5 10 15 20 25 30 35 40 45 Identity Consent Symptoms (COVID-19) Demographics Disability Employment Health Insurance Health Status Housing Medical History Medications Vaccine Hesitancy
  • 60. Specific Concerns • Community/Participant Concerns: • CDE may impact participants’ comfort, willingness to getting tested • Community trust will be impacted by collection of sensitive CDE (ex. identity) • Participant burden due to length of CDE • Wording of some CDE are not culturally sensitive • Data sovereignty and sharing concerns associated with specific communities
  • 61. Specific Concerns • Project Concerns: • Design of the project does not support CDE • Survey is anonymous, so not obtaining consent • Not enrolling individual participants / only have aggregate data • High volume of visits per hour won’t allow for full CDE collection • Staff burden • Training needed for interviewers to administer the CDE as an oral interview • Already IRB approved / started project / enrolling participants • IRB or institution will not approve sharing some CDE with RADx-UP CDCC • CDE do not align with the project’s specific goals or hypotheses • Already asking similar questions/topics in project’s questionnaires • Terminology in some CDE needs to be defined (ex. “stable housing”)
  • 62. Specific Concerns • Relatedness to RADx-UP Goals • CDE focus should be more on conditions and situations directly related to COVID-19 • Collecting extensive CDE to create a standard, long-standing, epidemiological dataset may impact the ability to actually meet the project’s goals and the testing goals of RADx-UP

Editor's Notes

  1. Warren
  2. Warren
  3. Warren
  4. Warren
  5. Warren
  6. Warren
  7. Warren
  8. Warren
  9. Micky – on behalf of myself, Giselle, and Warren and the entire RADx-UP CDCC we’d like to welcome you to today’s Project-Wide Monthly Team Meeting.
  10. Warren - Here are highlights of new and recent activity from the RADx-UP CDCC, as well as a few upcoming activities. Please refer to the RADx-UP CDCC Newsletter that was sent last Friday. You can find all of the newsletters on the Toolkit page of radx-up.org
  11. Warren
  12. Warren – handover to Cedric
  13. Giselle
  14. Giselle
  15. Giselle
  16. Giselle
  17. Giselle
  18. Warren
  19. Warren
  20. Warren
  21. Warren
  22. Warren
  23. Warren
  24. Warren
  25. Warren
  26. Warren
  27. Warren
  28. Warren
  29. Warren
  30. Warren
  31. Warren
  32. Warren